Dr. Westover is a physician-scientist with expertise in structural biology, enzymology, and structure-based drug design. His lab at UTSW played a pivotal role in co-developing some of the first KRAS G12C inhibitors, demonstrating their potential as an anti-cancer strategy. They further characterized structural, biochemical, and biological differences between specific KRAS mutations found in human diseases, paving the way for allele-specific, RAS-directed anti-cancer therapies. The lab's co-development efforts extend to kinase inhibitors targeting mTOR, TAK1, CDK7, CDK11, HER3, DCLK1, JNK2, SRMS, and SRC. Beyond his targeted inhibitor research, Dr. Westover is Chief of Thoracic Service for Radiation Oncology at UT Southwestern actively practices as a thoracic radiation oncologist and leads clinical trials in radiation oncology.